Arcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America

MT Newswires Live01-26

Arcutis Biotherapeutics (ARQT) said Monday it terminated its promotion agreement for Zoryve with Kowa Pharmaceuticals America on Friday.

The agreement covered sales and promotion of the Zoryve cream by Kowa to pediatricians and primary care physicians in the US, according to the company.

Arcutis said it now intends to oversee sales and promotion of Zoryve itself in the pediatric and primary care settings, as Kowa will now halt all activities of the cream, while the company will not be entitled to pay any further payments.

Arcutis also said it anticipates to remain cash flow breakeven and expects no negative impact from this change on its 2026 net product sales outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606246629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606246629","market":"sg","top_or_hot":-1,"title":"Arcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARQT\">Arcutis Biotherapeutics</a> (ARQT) said Monday it terminated its promotion agreement for Zoryve with Kowa Pharmaceuticals America on Friday.</p><p>The agreement covered sales and promotion of the Zoryve cream by Kowa to pediatricians and primary care physicians in the US, according to the company.</p><p>Arcutis said it now intends to oversee sales and promotion of Zoryve itself in the pediatric and primary care settings, as Kowa will now halt all activities of the cream, while the company will not be entitled to pay any further payments.</p><p>Arcutis also said it anticipates to remain cash flow breakeven and expects no negative impact from this change on its 2026 net product sales outlook.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-26 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARQT\">Arcutis Biotherapeutics</a> (ARQT) said Monday it terminated its promotion agreement for Zoryve with Kowa Pharmaceuticals America on Friday.</p><p>The agreement covered sales and promotion of the Zoryve cream by Kowa to pediatricians and primary care physicians in the US, according to the company.</p><p>Arcutis said it now intends to oversee sales and promotion of Zoryve itself in the pediatric and primary care settings, as Kowa will now halt all activities of the cream, while the company will not be entitled to pay any further payments.</p><p>Arcutis also said it anticipates to remain cash flow breakeven and expects no negative impact from this change on its 2026 net product sales outlook.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606246629","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606246629","pubTimestamp":1769437419,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arcutis Biotherapeutics  said Monday it terminated its promotion agreement for Zoryve with Kowa Pharmaceuticals America on Friday.The agreement covered sales and promotion of the Zoryve cream by Kowa to pediatricians and primary care physicians in the US, according to the company.Arcutis said it now intends to oversee sales and promotion of Zoryve itself in the pediatric and primary care settings, as Kowa will now halt all activities of the cream, while the company will not be entitled to pay any further payments.Arcutis also said it anticipates to remain cash flow breakeven and expects no negative impact from this change on its 2026 net product sales outlook.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc.","BK4139":"生物科技"},"translate_title":"Arcutis终止与Kowa Pharmaceuticals America的Zoryve推广协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics (ARQT) said Monday it terminated its promotion agreement for Zoryve with Kowa Pharmaceuticals America on Friday.The agreement covered sales and promotion of the Zoryve cream by Kowa to pediatricians and primary care physicians in the US, according to the company.Arcutis said it now intends to oversee sales and promotion of Zoryve itself in the pediatric and primary care settings, as Kowa will now halt all activities of the cream, while the company will not be entitled to pay any further payments.Arcutis also said it anticipates to remain cash flow breakeven and expects no negative impact from this change on its 2026 net product sales outlook.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606246629","isCrawlerRequest":true}